NEW YORK (GenomeWeb) – Diagnostics developer Venaxis and privately held genomics company Strand Life Sciences announced today that they are terminating their proposed merger.

The companies noted that they determined they could not complete the terms of their deal in a timely enough manner and that the uncertainty was negatively affecting their respective plans.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.